STAG Industrial remains a 'Buy' in my portfolio due to improving market conditions and solid Q1 2025 results. The industrial real estate sector faced challenges from oversupply and rising vacancies post-COVID, pressuring valuations and rent growth. STAG has historically outperformed market rent growth, but current conditions suggest less dynamic rent increases ahead.

Silvercorp (SVM) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago.

Gold edged higher in the early Asian session, supported by lingering worries over ballooning U.S. deficits, which typically bolster the safe-haven appeal of the precious metal.

United Airlines is capitalizing on strong international demand and a shift to premium offerings, driving record earnings and solid financial performance. The 'United Next' initiative focuses on expanding premium cabin capacity, enhancing customer experience, and leveraging technology partnerships like Starlink Wi-Fi. Financial discipline is evident with rising free cash flow, robust liquidity, and active share buybacks, despite a high debt load.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc. (NASDAQ:NTLA) on behalf of long-term stockholders following a class action complaint that was filed against Intellia on February 11, 2025 with a Class Period from July 30, 2024 to January 8, 2025. Our investigation concerns whether the board of directors of Intellia have breached their fiduciary duties to the company.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Semler Scientific Inc. (“Semler” or the “Company”) (NASDAQ:SMLR) on behalf of Semler stockholders. Our investigation concerns whether Semler has violated the federal securities laws and/or engaged in other unlawful business practices.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Apple Inc. (“Apple” or the “Company”) (NASDAQ:AAPL) on behalf of Apple stockholders. Our investigation concerns whether Apple has violated the federal securities laws and/or engaged in other unlawful business practices.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ADTRAN Holdings, Inc. (“ADTRAN” or the “Company”) (NASDAQ:ADTN) on behalf of ADTRAN stockholders. Our investigation concerns whether ADTRAN has violated the federal securities laws and/or engaged in other unlawful business practices.

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Autodesk, Inc. (NASDAQ:ADSK ) Q1 2026 Earnings Conference Call May 22, 2025 5:00 PM ET Company Participants Simon Mays-Smith - VP, IR Andrew Anagnost - CEO Janesh Moorjani - CFO Conference Call Participants Saket Kalia - Barclays Jay Vleeschhouwer - Griffin Securities Adam Borg - Stifel Jason Celino - KeyBanc Capital Markets Elizabeth Porter - Morgan Stanley Bhavin Shah - Deutsche Bank Joe Vruwink - Baird Taylor McGinnis - UBS Michael Turrin - Wells Fargo Siti Panigrahi - Mizuho Ken Wong - Oppenheimer & Company Joshua Tilton - Wolfe Research Tyler Radke - Citi Operator Thank you for standing by, …

Amazon's latest shareholder results, released Thursday afternoon, show a continued decline in support for some high-profile environmental and social proposals.

StepStone Group Inc. (NASDAQ:STEP ) Q4 2025 Results Conference Call May 22, 2025 5:00 PM ET Company Participants Seth Weiss - Head, Investor Relations Scott Hart - Chief Executive Officer Mike McCabe - Head-Strategy David Park - Chief Financial Officer Jason Ment - President and Co-Chief Operating Officer Conference Call Participants Ken Worthington - JPMorgan Ben Budish - Barclays Michael Cyprys - Morgan Stanley Chris Kotowski - Oppenheimer Operator Thank you for standing by, and welcome to the StepStone Group's Fiscal Fourth Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Ibotta, Inc. (NYSE:IBTA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ibotta-lawsuit-submission-form?prid=149862&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your UnitedHealth Group Incorporated (NYSE:UNH) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/unitedhealth-group-incorporated-lawsuit-submission-form?prid=149863&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=149861&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors will be presented during an oral presentation and poster presentation, respectively, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 - June 3 in Chicago, Ill., USA. Both lisaftoclax and alrizomadlin demonstrated antitumor activity, and the data support their further clinical development.

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of UnitedHealth Group Incorporated (NYSE: UNH) between December 3, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline in the securities class action commenced by the firm.

SAN DIEGO , May 22, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons or entities that purchased or otherwise acquired Ibotta, Inc. (NYSE: IBTA) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Ibotta's April 18, 2024 initial public offering, or between April 18, 2024 and February 26, 2025. Ibotta purports to be a technology company that allows consumer packaged goods brands to deliver digital promotions to millions of consumers through its network called the Ibotta Performance Network.

NEW YORK , May 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the "Class Period"), of the important June 3, 2025 lead plaintiff deadline. So what: If you purchased Viatris securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.